Editorial
Treatment of Late Stage Non-small Cell Lung Cancer: We Have More Work to Do
Abstract
The successful treatment of non-small cell lung cancer (NSCLC), like most solid tumors, still relies on complete surgical resection. However, a meaningful disease-free interval with surgery alone has been typically restricted to early stages I and II. Over the years, we have made slight improvements in the overall survival and quality of life for patients with more advanced stages, although these improvements have been relegated to patients with a “decent” performance status who can tolerate more intense combined modality therapy or chemotherapy alone.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.